Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Trial Details
- NCT ID
- NCT04906096
- Phase
- PHASE2
- Sponsor
- Lakshmi Nayak, MD
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Boston, Massachusetts, United States|42.35843,-71.05977
- Boston, Massachusetts, United States|42.35843,-71.05977
Key Eligibility Criteria
- Participants must be able to understand and willing to sign a written informed consent document.
- Participant must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines…
- Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
- Participants must be at least 18 years old on day of signing informed consent.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →